Journal article
Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures
M Toledo, J Whitesides, J Schiemann, ME Johnson, K Eckhardt, B McDonough, S Borghs, P Kwan
Epilepsia | WILEY-BLACKWELL | Published : 2016
DOI: 10.1111/epi.13416
Abstract
Objectives: To report pooled safety/tolerability and seizure outcome data from adults with uncontrolled partial-onset (focal) seizures (POS) receiving adjunctive brivaracetam (BRV) during phase IIb/III and long-term follow-up (LTFU) studies. Methods: Seizure outcome data were pooled from phase IIb (NCT00175929 and NCT00175825), III/IIIb (NCT00490035, NCT00464269, NCT00504881, and NCT01261325) and associated LTFU studies (NCT00175916, NCT00150800, and NCT01339559). Safety/tolerability data were pooled from these studies plus NCT01405508, NCT01653262, and NCT01728077 (LTFU). Patients received placebo (during core studies) or BRV 5–200 mg/day. Safety/tolerability and seizure outcomes (BRV modal..
View full abstractGrants
Funding Acknowledgements
This study was funded by UCB Pharma, which was involved in the design and conduct of the study; collection, management, and analysis of the data; and preparation and review of the manuscript. The authors acknowledge Mark Hughes and Sally Cotterill (QXV Comms, an Ashfield Business, part of UDG Healthcare plc, Macclesfield, United Kingdom) for writing assistance, which was funded by UCB Pharma.